Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 30, 2012

BioClinica, Mirada Medical Ally to Expand Use of Molecular Imaging in Clinical Trials

  • BioClinica and Mirada Medical are partnering to integrate Mirada's XD3 software solution into BioClinica’s imaging technology. Companies say this will enhance PET capabilities and expertise for molecular imaging trials.

    After a careful evaluation of available molecular imaging solutions, BioClinica selected Mirada for its advanced image analysis capabilities and ability to handle not only PET images but CT and MRI as well. Mirada Medical's software provides tools and efficient workflows for the quantification and tracking of findings for major modalities. This will further enhance BioClinica's image registration and fusion capabilities in studies where multiple modalities are utilized.

    BioClinica will integrate Mirada's XD3 image analysis software platform into its processes and workflows, adopting an innovative design that will advance the clinical capabilities of BioClinica technologies such as BioPACS and BioREAD.

    Through this partnership, BioClinica's PET image processing capabilities will extend oncology clinical trials with support for the following features: enhanced capabilities for PERCIST tumor response assessment criteria; normalization of uptake by body weight, lean body mass, or body; surface area for SUV measurements; registration and fusion capabilities between PET, CT, and MR; and customizable workflow and user interface to provide flexibility in the independent read design.

    "Adding Mirada technology to our oncology trial process takes BioClinica's already robust imaging core lab services to a new level," remarks Andy Dzik-Jurasz, BioClinica's senior medical director of medical affairs. "By adding XD3 to our workflow, BioClinica will offer the most sophisticated level of clinical analysis available for oncology PET scan image processing."



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »